A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
A phase 2 trial of Bexobrutideg in chronic lymphocytic leukaemia, run by Nurix Therapeutics, Inc., now recruiting.
Overview
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) is a phase 2 interventional study registered as NCT07221500 by Nurix Therapeutics, Inc., with 100 participants planned, started 2025-10-15 and due to reach its primary completion in 2028-01. Interventions recorded: NX-5948.
Similar pages
not linked directly; found by shared links- TrialStudy of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Shares Bexobrutideg, Nurix Therapeutics, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialStudy of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Shares Bexobrutideg, Nurix Therapeutics, Chronic lymphocytic leukaemia.
- TrialA Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
Shares Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies
Shares Chronic lymphocytic leukaemia and the tag pipeline.
- TrialStudy of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
Shares Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Shares Chronic lymphocytic leukaemia and the tag pipeline.
- TrialACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
Shares Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
Shares Chronic lymphocytic leukaemia and the tag pipeline.